GoodRx and Novo Nordisk unveil $499 monthly offer for Ozempic and Wegovy

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy (semaglutide) available to eligible self-paying patients for $499 per month. The move marks the first time Ozempic has been offered at this price point.

“Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,” said Wendy Barnes, chief executive officer of GoodRx. Dave Moore, executive vice president of Novo Nordisk’s US operations, added that the initiative helps reach patients “with our authentic GLP-1 medicines” at a new lower cost.

The program will run through GoodRx’s pharmacy network of more than 70,000 outlets nationwide, with home delivery options available. The companies said the offer aims to expand access to authentic, FDA-approved medicines, particularly for the millions who lack insurance coverage for obesity care.